NEW YORK A Missouri appeals court overturned a $110 million verdict against Johnson & Johnson in a lawsuit by a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.
The Trump administration will announce plans to change healthcare regulations on Wednesday to loosen anti-kickback provisions that restrict the kinds of outside services providers can refer patients to, administration officials said.
A jury award that hit Johnson & Johnson with $8 billion in punitive damages for a case involving its anti-psychotic drug Risperdal highlights the risks of the drugmaker's all-or-nothing legal strategy, several legal experts told Reuters on Wednesday. | Video
Oct 9 The Trump administration on Wednesday
proposed changes to federal anti-kickback provisions that
restrict the kinds of patient referrals doctors can make, saying
it will improve healthcare coordination and foster payments
based on the quality of care.
Sept 5 Credit Suisse Group AG has
brought on three new senior investment bankers as it continues
to build out its healthcare investment banking division,
according to an internal memo reviewed by Reuters.
The Trump administration is appealing a court ruling that struck down its plan to compel pharmaceutical companies to disclose wholesale prices of their drugs in televisions advertisements.
Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.
Aug 19 Private equity firm Centerbridge Partners
LP has made a significant investment in GoHealth LLC, giving the
online health insurance marketplace a major new financial backer
at a time when the insurance industry is bracing for change.
Aug 18 Private equity firm Centerbridge Partners
LP is nearing a deal to acquire a majority stake in GoHealth LLC
that could value the U.S. online health insurance marketplace at
about $1.5 billion, people familiar with the matter said on
Mylan NV's planned merger with Pfizer Inc's off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.